Trials / Unknown
UnknownNCT04242927
A Study to Investigate Nicotinic Acid on VEGFR Inhibitor-Associated Hand-Foot Skin Reactions
Efficacy of Nicotinic Acid for VEGFR Inhibitor-Associated Hand-Foot Skin Reactions in Solid Tumor Patients: a Randomised Controlled Phase 2 Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- First People's Hospital of Hangzhou · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Hand-Foot Skin Reaction (HFSR) is a common adverse event induced by Vascular Endothelial Growth Receptor Inhibitor (VEGFRi) in cancer patients. The main purpose of this study is to evaluate the efficacy and safety of nicotinic acid in solid tumor patients with grade II/III VEGFRi-associated HFSR.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nicotinic acid +Routine care | Nicotinic acid is administered orally at 50 mg (grade 2) or 100 mg (grade 3) three times daily with routine care. |
| DRUG | Routine care | Routinely apply urea ointment and provide best supportive care. |
Timeline
- Start date
- 2020-03-09
- Primary completion
- 2021-03-09
- Completion
- 2022-03-09
- First posted
- 2020-01-27
- Last updated
- 2020-04-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04242927. Inclusion in this directory is not an endorsement.